Ингибиторы нейраминидазы вируса гриппа - препараты выбора при эпидемиях и новой пандемии

17.08.2009

Литература

  1. Ленева И.А., Глушков Р.Г., Гуськова Т.А. Лекарственные средства для химиотерапии и химиопрофилактики гриппа: особенности механизма действия, эффективность и безопасность // ХФЖ. 2004. Т. 38. № 11. С. 8 - 14.
  2. Колобухина Л.В., Меркулова Л.Н., Бурцева Е.И. и др. Эффективность озельтамивира (Tamiflu™) при гриппе у взрослых во время эпидемического подъема заболеваемости в России в сезоне 2006 -2007 гг. // Вопр. вирусол. 2008. № 4. С. 23 - 26.
  3. Aoki F.Y., Macleod M.D., Piggiaro P. et al. Early administration of oral os-eltamivir increases the benefits of influenza treatment // J. Antimicrob. Chemother. 2003. 51. P. 123 - 129.
  4. Carr J., Ives J., Kelly L. et al. Influenza virus carring neuraminidase with reduced sensitivity to oseltamivir carboxylate has alered properties in vitro and is compromised for infectivity and replicative ability in vivo // Antivir. Res. 2002. 54 (2). P 79 - 88.
  5. Colman P.M., Varghese J.N., Laver W.C. Structure of the catalytic and an-tigenic sites in influenza virus neuraminidase // Nature. 1983. № 303.P. 41 - 44.
  6. Diggory P., Fernandes Ch., Humphrey A. et al. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomized controlled trial // BMJ. 2001. V. 322. P 577 - 579.
  7. Gravenstein S., Drinka P., Osterweil D. et al. A multicenter prospective double-blind randomized controlled trial comparing the relative safety and efficacy of zanamivir to rimantadine for nursing home influenza outbreak control // Abstracts of the 40-th Interscience Conference on Antimicrobal Agents and Chemotherapy, Washington, DC: Am. Soc. for Microbiol. 2000.P. 270.
  8. Fitz R.S., Hayden F.G., Calfee D.P. et al. Nasal cytokine and chemokine responses in experimental influenza virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment // J. Infect. Dis. 180.P. 586 - 593.
  9. Freund B., Gravenstein S., Elliott M. et al. Zanamivir - a review of clinical safety // Drug Suf. 1999. № 21. P. 267 - 281.
  10. Hayden F.G., Osterhaus A.D., Treanor J.J. et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infection // N. Engl. J. Med. 1997. 337(13). P. 874 - 879.
  11. Hayden F.C., Gubareva L.V., Monto A.S. et al. Inhaled zanamivir for prevention of influenza in families. Zanamivir Family Study Group // N. Eng. J.Med. 2000. V. 343. P. 1282 - 1289.
  12. Hayden F.G. Perspectives on antiviral use during pandemic influenza // Phil. Trans. R. Soc. Lond. B. 2001. V. 356. P. 1877 - 1884.
  13. Hayden F. Pandemic influenza - is an antiviral response realistic?// Pe-diatr. Infect. Dis. J. 2004. 23 (11). P. 262 - 299.
  14. Hayden F.G., Aoki F.Y. Influenza neuraminidase inhibitors. / Yu V.L. et al. (Eds.). Antimicrobial Therapy and Vaccines. V. 2. Second ed. - E. Sun Technologies, LLC, Pittsburgh, PA. 2002. P. 773 - 789.
  15. Kaiser L., Henry D., Flack N.P. et al. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study // Clin. Infect.Dis. 2000. V. 30. P. 587 - 589.
  16. Kaiser L., Keene O.N., Hammond J.M.J. et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults // Arch. Intern. Med. 2000. 160. P. 3234 - 3240.

Д.К. Львов, Е.И. Бурцева Ингибиторы нейраминидазы вируса гриппа препараты выбора при эпидемиях и новой пандемии // Эпидемиология и вакцинопрофилактика 2009, №47, стр. 44-48